Abstract
Objective: To identify the economic burden of diabetes management in a middle-income country and its causes. Methods: Evaluative research based on a longitudinal-type design. We used the Kessner criteria and cost technology by instrumentation. For the estimation of epidemiological changes, we developed some models under the Box–Jenkins technique for the period of time 2014–2016. The financial requirements were obtained from case management costs expected by disease and the application of an econometric adjustment factor to control effects of inflation. Results: Comparing the economic impact in 2013 versus 2015 (p < 0.05), there is a 26% increase in financial requirements. The total amount for diabetes in 2015 (US dollars) was $ 8,974,662,570. It includes $ 3,981,426,810 in direct costs and $ 4993,235,752 in indirect costs. The total direct costs expected are $ 473,135,561 for the Ministry of Health (SSA), serving to uninsured population, $ 1318,506,546 for insured population (Mexican Institute for Social Security (IMSS) and Institute for Social Security and Services for State Workers (ISSSTE)), $ 2070,341,961 to users, and $ 119,442,750 to private health insurance (PHI). Conclusions: If the risk factors and the different health-care models remain as they are currently in the institutions analyzed, the financial consequences would be of major impact for the pockets of the users, following in order of importance, IMSS, SSA, and finally ISSSTE. We suggest rethinking the process of planning, organization and allocation of resources, in terms of demand for hospital and outpatients services for patients with diabetes. On the other hand, it suggests fundamental changes in the care model, increasing significantly resources and strategies toward greater prevention and primary care actions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arredondo A, Orozco E. Libro Gerencia y Economía en Salud. Indicadores epidemiológicos y económicos: Aportes de la economía de la salud. Centro Interamericano de Estudios en Seguridad Social. Mexico, DF. ISBN: 968-6748-39-3; 2014. p. 91–112.
Pinzón Flórez CE, Chapman E, Panisset U, Arredondo A, Fitzgerald J, Reveiz L. Disponibilidad de indicadores para el seguimiento del alcance de la “Salud Universal” en América Latina y el Caribe. Rev Panam Salud Pública. 2016;39(6):330–40.
Arredondo A, Barceló A. The economic burden of out-of-pocket medical expenditures for patients seeking diabetes care in Mexico. Diabetologia. 2007;50:435–6.
Instituto Nacional de Salud Pública. Métodos de estimación de demanda esperada de enfermedades crónico-degenerativas. Informe Técnico de Memoria Metodológica. Cuernavaca, México. Febrero del 2017. p. 63–78.
Arredondo A, Zuñiga A. Economic burden of diabetes in middle-income countries: the Mexican case. Diabetes Care. 2004;29:104–9.
Secretaría de Salud, Información básica sobre recursos y servicios del Sistema Nacional de Salud. Informe Técnico. 2016. p. 68–76.
Panamerican Health Organization, Health Analysis and Information Systems, Regional Mortality Database. 2016. p. 23–37.
Caro J, Ward A, O’Brien J. Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S. Diabetes Care. 2002;25:476–81.
Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159:1873–80.
International Diabetes Federation. Direct cost to the health care sector. Brussels: Diabetes Health Economics, International Diabetes Federation; 2015. p. 13–5.
Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada. Diabetes Care. 2002;25:1303–7.
Barcelo A, Daroca MC, Ribera R, Duarte E, Zapata A, Vohra M. Diabetes in Bolivia. Rev Panam Salud Publica. 2001;10:318–23.
International Diabetes Federation. Direct cost to the health care sector. Brussels: Diabetes Health Economics, International Diabetes Federation; 2015. p. 29–35.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2014;27:1047–53.
Herman WH, Eastman RC. The effects of treatment on the direct cost of diabetes. Diabetes Care. 1998;21(Suppl 3):19–24.
Arredondo A. Out-of-pocket costs to users: medicine options for hypertension. Am J Hypertension. 2008;21:443.
Murray A. Chap. 2: Statistical modelling and statistical inference: measurement error in the explanatory variables. Box-Jenkins technique. In: Statistical modelling in GLIM. 3rd ed. New York: Oxford Science Publications, Ox. Uni. Press; 2005. p. 112–32.
Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81:19–27.
Banco de México, editor. Indice Nacional de Precios por Servicios Médicos en México. Cuadernos Mensuales, Base 1998=100. La Actividad Económica en México. 1983–2012. Gerencia de Investigación Económica. México, DF: Banco de México Ed; 2016. p. 46–68.
Arredondo A. Changing paradigms and challenges: evidence from epidemiological and economic burden of diabetes in Latin America. Diabet Med. 2017;34(7):1009–10.
American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32.
Zhang P, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res. 2010;87:293–301.
Bommer C, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017;5(6):423–30.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix 1. Model Format to Determine Production Costs by Diabetes Case Management
Appendix 1. Model Format to Determine Production Costs by Diabetes Case Management
Institution -------------------------------------------------------- Production function ------------------------------------------------------------
Type of input | Measure unit | Unit cost | Quantity by case management | Average cost | Equation of depreciation | Total cost |
|---|---|---|---|---|---|---|
Human resources | ||||||
Equipment and furniture | ||||||
Drugs | ||||||
Diagnostic studies, etc. Infrastructure Maintenance services General services Total cost |
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Arredondo, A., Orozco, E., Duarte, M.B., Cuadra, S.M., Recamán, A.L., Azar, A. (2019). Economic Costs, from Individuals to Health Systems: Evidence from a Middle-Income Country. In: Rodriguez-Saldana, J. (eds) The Diabetes Textbook. Springer, Cham. https://doi.org/10.1007/978-3-030-11815-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-11815-0_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-11814-3
Online ISBN: 978-3-030-11815-0
eBook Packages: MedicineMedicine (R0)